GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome

Epigenetic inactivation of GPX3 has been identified in various cancers including leukemia. Moreover, aberrant DNA methylation was also found as a dominant mechanism of disease progression in myelodysplastic syndrome (MDS). This study intended to explore GPX3 promoter methylation and its clinical rel...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Med
Main Authors: Zhou, Jing‐Dong, Lin, Jiang, Zhang, Ting‐Juan, Ma, Ji‐Chun, Yang, Lei, Wen, Xiang‐Mei, Guo, Hong, Yang, Jing, Deng, Zhao‐Qun, Qian, Jun
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Cancer Biology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5269561/
https://ncbi.nlm.nih.gov/pubmed/27891827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.984
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki